| Typicality: | 0.332 |
| Saliency: | 0.193 |
| in this phase ii trial | 7 | location |
| across three large cancer centers | 7 | location |
| colleague → enrol → 147 patients | 7 |
| negative | neutral | positive |
| 0.072 | 0.877 | 0.051 |
| Raw frequency | 7 |
| Normalized frequency | 0.193 |
| Modifier score | 0.500 |
| Perplexity | 379.860 |